Dermata Therapeutics, Inc. financial data

Symbol
DRMA, DRMAW on Nasdaq
Industry
Pharmaceutical Preparations
Location
3525 Del Mar Heights Rd., #322, San Diego, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 29.3 % +101%
Return On Equity -197 % -81.9%
Return On Assets -153 % -61.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.32M shares -58.7%
Common Stock, Shares, Outstanding 693K shares -78.3%
Entity Public Float 4.8M USD +20%
Common Stock, Value, Issued 69 USD -78.4%
Weighted Average Number of Shares Outstanding, Basic 8.35M shares +337%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.65M USD +26.2%
General and Administrative Expense 4.47M USD +21%
Operating Income (Loss) -10.1M USD -23.9%
Net Income (Loss) Attributable to Parent -9.82M USD -22.2%
Earnings Per Share, Basic -2.67 USD/shares +80.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.63M USD -17.8%
Assets 5.24M USD -39.9%
Accounts Payable, Current 1.33M USD +203%
Liabilities 1.92M USD +181%
Retained Earnings (Accumulated Deficit) -59.4M USD -19.8%
Stockholders' Equity Attributable to Parent 3.32M USD -58.7%
Liabilities and Equity 5.24M USD -39.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.7M USD -63.9%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 693K shares -78.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.95M USD -41.4%
Deferred Tax Assets, Valuation Allowance 5.46M USD +47.3%
Deferred Tax Assets, Gross 5.46M USD +47.3%
Deferred Tax Assets, Operating Loss Carryforwards 2.98M USD +54.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 645K USD +15.8%
Additional Paid in Capital 62.7M USD +8.87%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 235K USD +64.7%
Interest Expense 655 USD -100%